thanks for the warm welcome!

2008-11-30 22:46:15

Hi Pam, and group,]
I'm new to this group, but have read many posts from other sites,
from some of you. Thank goodness for these support groups, I feel
like SOMEBODY understands what I'm going through. This is my second
round of treatment, beginning month 6 tonight. :-{
I so look forward to chatting with you all, and even figured out how
to post a message, and my pic. (Old pic, 9 yrs, but everything about
me has changed, with this disease).
I love to have fun, but lacking the energy at the moment.
Write anytime!
hugs, and prayers,
Donna

Re: [HepCingles2] Mykal!

2008-11-30 13:55:42

Well Pam thanks I think I will give computer programing a try, or at least word
processing I also am entertained by the prospect of becomming a professional
student lol that would be nice lol I will major in Phishtheology
lol....Phish;the next greatful dead!! I heard a mimic band called the dreadful
grapes that was pretty good too though it doesnt matter because as Mark Lindsey
said (quoting Mick Jagger) Tiiime is on my side, yes it is Tiiime is on my
side, yes it is Now your always sayin...........

Re: [HepCingles2] Philly

2008-11-30 13:03:43

yea if you drink at all the anti-D's are a placebo too

Mykal!

2008-11-30 07:27:18

Hey there Mykal!! I am so glad to see you back and posting and doing so
well :-) Good for you for staying in the *exercise* mode! It really does
help...........and your brain fog isn't permanent so what are you going to
take in school?! I think that is wonderful that you are going to go back
:-) GO MYKAL!
Peace and Love,
·´¨¨)) -:¦:-
¸.·´.·´¨¨))
((¸¸.·´ ..·´ -:¦:-Pam
-:¦:- ((¸¸.·´*
"In a cat's eye, all things belong to cats." - English proverb

Philly

2008-11-29 19:52:05

Good advice Steve! :-) Welcome to our little family *Philly* and what you
are experiencing it is what is endearingly called *riba rage* :-) Alot of
us started an antiDepressant right before starting treatment just to avoid
alot of those feelings. It definitely is a good idea for most everyone to
take an antiD during treatment. Alcohol is not only bad for your liver
just because we have liver disease but if you drink while taking the
treatment your chances of clearing the virus are greatly diminished so why
would you want to put yourself through treatment just to NOT have it
work?!?!? :-) Definitely don't drink anymore. I know several people who
drank through their first round of treatment, didn't clear the virus,
FINALLY stopped drinking and did treatment AGAIN and DID clear the virus.
What a hard way to learn that lesson :-) Take care of yourself and I
think most of us learned 90% of what we know from all of these wonderful
lists!! It really does help to have each other to talk to!
Peace and Love,
·´¨¨)) -:¦:-
¸.·´.·´¨¨))
((¸¸.·´ ..·´ -:¦:-Pam
-:¦:- ((¸¸.·´*
"In a cat's eye, all things belong to cats." - English proverb

Cody

2008-11-29 14:55:01

Hey there Cody and thanks for sharing your story :-) So similar to alot of
ours. One day feeling pretty good and the next day BAM, the crummy
diagnosis and our lives changed forever :-( Glad to hear that you are
trying to keep an upbeat attitude. I do believe that is a key to this.
Don't beat yourself up over bad days though. We all have them! I really
wasn't a big ice cream fan until I got this diagnosis. Now I eat it on my
*down days* quite regularly LOL Take care of yourself and please know
we are all here for anything you, or anyone else, might need :-)
Peace and Love,
·´¨¨)) -:¦:-
¸.·´.·´¨¨))
((¸¸.·´ ..·´ -:¦:-Pam
-:¦:- ((¸¸.·´*
"In a cat's eye, all things belong to cats." - English proverb

Lynn/Trish

2008-11-29 11:59:10

I DO pick great friends, don't I Tricia? :-) and I pick YOU and Lynn
:-) Heppers have always been the bestest :-) LOL Take care!
Peace and Love,
·´¨¨)) -:¦:-
¸.·´.·´¨¨))
((¸¸.·´ ..·´ -:¦:-Pam
-:¦:- ((¸¸.·´*
"In a cat's eye, all things belong to cats." - English proverb

Meds

2008-11-29 08:22:02

We are all turning into *pharmacies* aren't we!! LOL Geez Tricia.......
sounds like you are on as many prn pills as I am and I KNOW that is alot!
LOL and my advice to Cody is to ask the doc how many Hep C patients he/she
has treated and if he/she would be *comfortable* treating a Hep C patient.
As you said Tricia, some of these *other type* docs in smaller towns can be
just as knowledgeable as the Hepatologist *gods* in the larger areas. Take
care of yourselves!
Peace and Love,
·´¨¨)) -:¦:-
¸.·´.·´¨¨))
((¸¸.·´ ..·´ -:¦:-Pam
-:¦:- ((¸¸.·´*
"In a cat's eye, all things belong to cats." - English proverb

Re: [HepCingles2] treatment/hepatitis

2008-11-29 02:33:51

Hey Philly,
The side effect you are experiencing is very common.Tell your Dr and ask him to
prescribe small amount of an anti depressent .It will take the edge off and you
will feel more comfortable. Do not drink alcohol.Drinking any amount of alcohol
when you have hcv is like throwing gasoline on a fire. Your liver would
deteriorate quicker.Even if the interfuron does not eliminate the disease (which
I hope it will ) it slows down the progression of the disease. In time there
will be better cures.
Good luck,
Steve.
phillybg <phillybg@...
I was diagnosed with hepc appx a year ago, and recently began
treatment on the interferon?? and ribavirin. Ive always been scared
to death of needles, I never thought I'd be able to give myself a
needle, but by the second time it was a breeze! I do check the
internet occasionally (which is how Ive found out 90 plus % of hep
info there is) but was wondering if anyones' come accross this: for
about the past few weeks Ive been incredibly moody and've had a
horrible "pissed off" type feeling...most of the time, but some times
I feel perfectly fine and even good....is this at all common with
this medication? also I know the doctor said never never take any
alchohol while on this medicine, but does anyone know actually what
would happen if one took alcohol? I know that its' bad for the
liver, thats why I've stayed away from it the past year. Just
wondering if anyone knows. thanks.

treatment/hepatitis

2008-11-28 15:23:16

I was diagnosed with hepc appx a year ago, and recently began
treatment on the interferon?? and ribavirin. Ive always been scared
to death of needles, I never thought I'd be able to give myself a
needle, but by the second time it was a breeze! I do check the
internet occasionally (which is how Ive found out 90 plus % of hep
info there is) but was wondering if anyones' come accross this: for
about the past few weeks Ive been incredibly moody and've had a
horrible "pissed off" type feeling...most of the time, but some times
I feel perfectly fine and even good....is this at all common with
this medication? also I know the doctor said never never take any
alchohol while on this medicine, but does anyone know actually what
would happen if one took alcohol? I know that its' bad for the
liver, thats why I've stayed away from it the past year. Just
wondering if anyone knows. thanks.

Re: [HepCingles2] Thank You Pam and Tricia

2008-11-28 08:50:16

Cody although I have never met anyone who is treated by a hemotologist they
do work with blood and if he is used to handling hep c it may be a good idea
to at least check him out. To me these fields do cross, interferon is a
chemotherapy that many oncologists use for breast cancer. I think the
gastro's got us by default but their is no rule of who to use just what is
best for you. I have had a couple internal med doc's that were educated and
good with hep. Depression is common with us all. I take elavil many here
take different ones. Who can be happy when they feel llike crap and their
world feels like it is crumbling around them? It is good you could trust
your ex to take the kids while you get this digested. I thank God I made it
through raising mine and am amazed at people who manage to take care of
small ones with this. I had hep b when my kids were young and my doc ordered
health home care, childcare etc. Back then insurance covered it all. My
biggest fear was not to make it to raising mine and getting them on their
own. I have one grown and out with a family of his own and my two babies are
in the Navy as is my son-in-law. Soon we will have a new baby as my daughter
is pregnant and due in August. I miss them so much but also am happy they do
not have to see how weak and out of it I really am. They pretty much try to
pretend I am okay and I pretend I am fine to them. I want them to be happy
not worrying about me. I too used to turn to ben and jerry's but they
stopped my favorite flavor and the extra water weight and health problems
turned me to ice pops or fruit popsciles. Sometimes I think I live on them.
I have more frozen fruit bars in my buggy or freezer than meat or anything
else. Thanks for coming out and giving us the pleasure of your company. I
live in north FL but my son is stationed in VA Beach and my mother-in-law
lives in Newport News. I have often looked up housing in northern VA. The FL
heat is hard on me in the summer but in the winter I am thankful to be here.
Take care and good luck with getting all the tests and info to arm you for
this ride. Oh for meds most of us are on water pills, I take aldactone, used
to use lasix and aldactone and had better results but the lasix is a little
harder on you I think. Sometimes I have to take potassium supplements cause
they play with your electrolytes. Also alot of us are on Klonopin as am I
for the nerves and ultram or something llike it for pain. Leg and joint pain
comes to a lot of us in a disease called fibromyalgia so alot of us get
celebrex which really helps with the leg and wrist pain I have but is hard
on your liver. I take it when I can't type from my wrist or can't walk right
with the leg pain. I have spent time in a wheelchair till I learned to
balance these drugs. I pretty much take everything on an as needed basis.
Something else you said about itching and rashes. The bile absorbs out of
your skin and causes bad itches. Atarax is common for that and I take that
daily. In the abscense of a script benadryl can sometimes help and my doc
used to give me shots of it. Sometimes you can about scratch your skin off
and that can leave it looking like rashes. Anyway I will shut up for a bit
getting to be nap time. Far as the sinse script I have thought of heading to
cal myself but transplant teams won't touch you if you go the natural way so
instead it take ten pills to do the same thing for you. LOL Hang tough,
together we will make it possible to walk this thorny path. smiles Tricia

Thank You Pam and Tricia

2008-11-28 05:53:49

Hello,
Thank you for your response and information. My real name is Cody, I
went ahead and created a extra profile and changed my group info. I
have just had this profile so long I did not think about it not
showing my real name ...... anyway - I was not referred by my family
doc to the hemotologist, I was taking a friend of my mom's to the
doctor for a checkup because she has cirrohsis and that is the kind
of doctor she goes to so I asked the nurse if he treated Hep C and
she said yes. I do not need a referall so I made an appt. I was at my
family doc for the other symptoms ( fluid etc. ) and I told him I had
made the appt. and he said he would monitor me. So now I have to do
something different because I do trust you guys. Plus what you say is
logical. So far my reg. doc has not given me anything for depression
or fluid. I guess he is waiting for me to get this infection resolved
and see my blood results!?? I reckon he could also be inventing a
pill to cure everything. ;) I generally am not a person to get
depressed but the other day I felt like being depressed so I didn't
fight it- sat down with Ben & Jerry Peanut Butter Me Up and chilled.
That worked. :o) ( still waiting for my sinsemillia script from
CA. ) LOL
In case you want to know a little history on me, I am 40 with 3 kids
who are staying with their mother for the first time in 5 years since
we seperated. It was hard to concentrate on this thing while raising
3 kids, it was easy to not think about since I had no symptoms. We
live in Virginia near Richmond out in the country. I had a bad work
accident in 94 and fought through a lot of ortho operations and
general bullshit and got my health back to the point that in 98 and
99 we lived in Montana and I worked as a hunting and fishing guide in
the Missoula - Kakispell area. So I know the importance of Positive
Thinking and Positive Living. I will not let this "Dragon" get the
best of me. From what I recall "Dragons" are not immortal just a lot
of hot air!!!
Anyway thanks to everyone for this group, it definitely works for me.
Cody

biopsy pain

2008-11-27 18:58:30

I was so sorry to read that your doc didn't prepare you a little better for
your biopsy. I had a really bad one but it was back in 1997 and I KNOW
things have improved since then. I have watched a couple of friends have
at about six of them and they never even blinked an eye. One needed a
little *cocktail* prior that kept him nice and calm but the other one didn't
take anything but had the area around the site numbed for it. Sure wish
you doc had told you about the sensation of *losing your breath* That in
itself can be very scary! I hope by now that you are feeling better and the
good news is that you won't have to do another one for quite awhile and you
will know what damage your liver has sustained :-) Please post us and let
us know what the results are. It usually takes about a week or so to get
them back. Take care of yourself!
Peace and Love,
Pam
Dogs come when they're called. Cats take a message and get back to you. --
Missy Dizick

Inter-Agency Advisory Regarding Claims That Smoked Marijuana Is a Medicine

2008-11-27 15:18:37

Two documents are cited in this post.
I have no personal involvement with marijuana as medicine or
otherwise but I am familiar with the research, it's potential in
diseases related to the immune system and immune response,
cancers/chemotherapies and also case histories that prove that it is
effective for some people with some conditions.
I am also familiar with the fact that the current Federal government
administration and it's Goons from the Drug Enforcement Agencies and
the like, are hell-bent on preserving alot of antiquated old school
perspectives on marijuana as an extremely harmful class I (the most
serious class of drugs) controlled substance. This administration
was also caught red handed a few years ago for tampering with and
very substantially altering scientific research data, in fact making
up some outright lies that were inserted into the research findings
(the MMDA or MDMA research scandal) to enhance their 'war on drugs'
politics and propaganda.
On April 20th, the FDA released the above inter-agency advisory
cited in the subject line.
The last paragraph reveals who (what agencies) are impacting the FDA
with respect to Medical Marijuana. I highly question why these anti-
drug goons are allowed to impact and virtually control the FDA on
this issue and further have the authority to police the medical
profession, on this issue and other issues such as pain medicines.
Here is the last paragraph. I have written out what the acronyms
stand for (within parenthses)
Quote:
legislative actions) making smoked marijuana available for a variety
of medical conditions upon a doctor's recommendation. These measures
are inconsistent with efforts to ensure that medications undergo the
rigorous scientific scrutiny of the FDA approval process and are
proven safe and effective under the standards of the FD&C Act. (Food
Drug and Cosmetics Act) Accordingly, FDA, (Food and Drug
Admisistration) as the federal agency responsible for reviewing the
safety and efficacy of drugs, DEA (Drug Enforcement Agency) as the
federal agency charged with enforcing the CSA,(Controlled Substances
Act) and the Office of National Drug Control Policy, as the federal
coordinator of drug control policy, do not support the use of smoked
marijuana for medical purposes. <
End Quote.
Here is the URL where you can read the whole FDA advisorywhich is
less than a page:
http://www.fda.gov/bbs/topics/NEWS/2006/NEW01362.html
Here is the second article of interest. This is a commentary on the
FDA Inter-Agency Advisory from the Editors of Scientific American, a
very well respected scientific journal:
Opinions, arguments and analyses from the editors of Scientific
American
April 21, 2006
11:50:10 am, Categories: Medicine, Politics and Science, 787 words
Medical Marijuana's Catch-22
http://blog.sciam.com/index.php?
title=medical_marijuana_s_catch_22&more=1&c=1&tb=1&pb=1
These few quoted paragraphs that follow say alot about this current
Federal Government, referring to a consistent pattern. I mentioned
just one of the scandals (MMDA or MDMA scandal) earlier but
apparently this is routine for the Bush administration. It has been
going on since the Nixon administration actually when the Controlled
Substances Act came into being- very clearly a gross corruption and a
deliberate circumvention of the spirit and intent of the US
Constitution- but that's another story:
quote:
that examined the research into marijuana's effects, said in an
interview that the statement on Thursday (By the FDA) and the
combined review by other agencies were wrong.
The federal government "loves to ignore our report," said Dr. Benson,
a professor of internal medicine at the University of Nebraska
Medical Center. "They would rather it never happened."
Some scientists and legislators said the agency's statement about
marijuana demonstrated that politics had trumped science.<<
End quote
The Scientific American Editor then writes the following:
Quote:
times in recent years have science reporters had to write some
version of that sentence? "Some scientists and legislators said the
[WHITE HOUSE/FEDERAL AGENCY]'s statement about [SUBJECT] demonstrated
that politics had trumped science" ought to be a Word macro.)<
End quote.
So apparently this is routine proceedure for the Bush administration.
I highly object to these military/police state war mongering goons
who are not only policing, intimidating and influencing the
scientific research and medical professions but also altering the
data and the results, twisting it to fit their pre-existing political
and propaganda agendas.
I don't even smoke marijuana for any reason, so marijuana isn't even
the issue. For me the real issue here is how these goons force
their political agenda on scientific research and the medical
professions.
I have been a direct victim of that a number of times when I was very
seriously in need effective pain medicines and could not get them
because of the DEA watching over the doctors shoulders, since I have
hepatitis-c which the DEA automatically presumes is due to drug abuse
and that people with hep-c are drug abusers. The hep-c doctors in
particular are over scrutinized and observed closely by the DEA and
the doctors are afraid to prescribe pain meds. The DEA determoines
HOW pain meds are to be prescribeds and if doctors make mistakes in
the DEA protocols they can lose their DEA license to prescribe pain
meds. That is another Catch 22 for the doctors.
The doctors and clinic management don't feel comfortable with
prescribing these pain medicines under these circumstances and in
one clinic where I have gone for several years all of the doctors
were banned from prescribing pain medicines except under
extraordinary circumstances and months of red tape, it was like
attempting to get an act from Congress to remedy the situation. This
is all due to the drug enforcement agencies mentioned in the quote
from the article. They have NO BUSINESS in Science and Medicine,
they belong crawling through a jungle or desert somewhere shooting
each other in my opinion.
So much for that topic. I just needed to express my distaste and
frustration over this issue
Dennis near Seattle

Re: [HepCingles2] tired of lurking : o )

2008-11-27 11:21:57

Glad you are speaking up. You do need a specialist, hopefully a heptolagist
but they are not readily available so most of us use gastro's. There is a
spot I think on hep central that lists doc's other heppers have had good or
bad experiences with or if you put out your city someone may know a good
doctor. The ones that keep up with hep are gems and sometimes as hard to
find. Some will tell you that you don't need to know your genotype but it
really is important regarding treatment. Also viral load is important even
if your alts are normal some doctors will say you are fine but some of us,
like me and Pam keep pretty much normal alts but high viral loads. The
amount of virus determines the damage it is doing as far as I know. I
qualify that cause I forget a lot now days. But for example my alts are
normal and my viral load is staying at or above 60+ million. I have
fibrosis, necrosis, chirosis, portal bridging and all the crap. An informed
doctor keeps me ready for a transplant in the horizon an uninformed one will
just check the alts and then won't know until it is too late if you are a
candidate for transplant. Some of us get the damage and some of us don't but
you deserve to know which group you are in and also the odds of treatment
which can only really be shown from what I have learned by genotype. I had 4
years on and off treatment, my doctors did not believe in genotyping. When
one did I had the resistant strain so I could probably take interferon
forever and not get lasting results. It is like quantam physics or
something. There are so many variables between each of us that we sorta have
to be our own activist in our treatment and the attitudes of the doctors we
choose. As far as I am concerned everyone with hep should at least have a
biopsy no matter how "normal" your alts are. I had biopsy's from no damage
to stage 2 grade3 to stage 3 grade 3 over the years. By stage 3 most doc's
are at least mentioning transplant and the best results I have seen are when
they are done early like stage 2. You will learn a lot and it will all
change or a different study will come up with something else so it is
frustrating to keep up and then when you get farther along you forget what
you did know. I think of my brain as a hep sponge. I have learned a lot but
sometimes you have to wring it out pretty hard for me to remember the latest
facts. Some people decide to just let it ride and for some that is fine if
it is moving slow but I have seen many go fast even having normal alts. Pam
can fix you up with a lot of reports or links etc as her mind is still more
in gear. I sorta went into ostrich mode for a while here. Anyway any help we
can be someone will have a opinion or a link or something to help you. I
know at first it is hard to jump in and put your personal life out here in
the air waves but you will be amazed how much of a family alot of heppers
are to each other. My "real" family has no idea what my world really entails
but my hep family has been here for it all. Good luck, Tricia

Re: [HepCingles2] Hemachromatosis - the Celtic Curse

2008-11-27 06:39:31

Pam I have a high is it ggp or what initial they give it from time to time.
It has never got high enough for them to bleed me or any severe measures.
LOL I have just been told never to take iron vitamins, really not any, and
I eat pretty sensibly when I eat. The last celtic curse site I found also
attributed all liver diseases to the genetics so I was kinds surprised to
find all the ones with just this hemochromatosis stuff on it. My family has
pretty much proved the theory having 2 liver deaths and me and my sister
both with hep now. Some of us are just born lucky hey? Maybe I'll start a
fire but I could of been polish or God forbid German so I will take the
celtic curse. To the rest of you I am not slamming your nationality's it is
a private joke. My sometimes husband is german and would like to run the
house like hitler so of course I try to cause havoc. He gets even by telling
me only crazy people would paint themselves blue, drop their clothes and
race into battle naked blasting pipes. Shoot I think it was pretty smart;
half the time the people just turned and ran thinking they were up against
some nuts. I think it was smart cause then the scots could concentrate on
making
the worst tasting whiskey in the world. LOL Tricia

RE: [HepCingles2] biobsy pain

2008-11-26 20:54:53

My shoulder hurt bad too. It is called referred pain. A few days after
the biopsy you should be feeling much better. To me the biopsy was a
very humbling experience. Just knew something bad was wrong to put you
through that. Just have to remember that is is necessary to see what
shape your liver is in.
Debbie
"Friendship is the hardest thing in the world to explain. It's not
something you learn in school. But if you haven't learned the meaning of
friendship, you really haven't learned anything."
-Muhammad Ali <http://www.quoteland.com/author.asp?AUTHOR_ID=431

A Bad Bottle Habit

2008-11-26 20:37:15

If you're in the habit of washing and reusing plastic water bottles, you may
want to limit the practice.
Washing water bottles before you reuse them can help cut down on illness-causing
bacteria. However, researchers caution that washing and reusing disposable water
bottles over and over may accelerate the breakdown of the plastic, increasing
your exposure to potentially harmful chemicals. Limit yourself to one or two
reuses.
In addition to repeated exposure to water and soap, disposable plastic water
bottles may be further degraded by exposure to sunlight. Store your bottled
water in a cool, dark place. Reuse disposable plastic water bottles for no
longer than a week or so, then recycle them.
http://www.realage.com/news_features/tip.aspx?cid=14358
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/13/2003

and the answere is

2008-11-26 15:00:40

6 month viral is CLEAR
w/a genotype 3..staying clear I'm told after tx at the six month mark, its as
good as GONE!!!
~Bayla~
"C" It! Treat It! Beat It!!
http://hometown.aol.com/nydragonslayer/
http://www.healsofnfl.bravehost.com/
http://hepcaware.org/

biobsy pain

2008-11-26 10:28:31

yesterday i went and had my first biopsy. the way the dr explained
it to me was, it is a very simple procedure shouldn't have any
problems. as soon as it was over i had extreme pain in my rt
shoulder than i felt like i couldn't breath. my stomach started
spasming, i thought i was gonna die. after 3 shots of moraphine and
2 loratabs, it subsided enough where i could breath, but my shoulder
is still hurting. has this happened to anyone else? if this is a
common accurance, why didn't they warn me. it wouldn't have been as
scarey when i could't catch my breath.

Mike

2008-11-25 21:52:13

Why thank you kind sir :-) Hope all is well at your end ;-)
Peace and Love,
Pam
Dogs come when they're called. Cats take a message and get back to you. --
Missy Dizick

HAPPY BIRTHDAY EWOB

2008-11-25 14:01:17

OopsssssI forgot your birthday!!!!!!! Happy birthday Pops
Tee

Re: [HepCingles2] Hello From Palm Springs CA

2008-11-25 11:29:32

Way to go Pam!!!!!!!!!!!!!!!!!!!!!!!!

Getting Disability Benefits Under Social Security with HCV

2008-11-25 06:41:21

Getting Disability Benefits Under Social Security with HCV
Jacques Chambers, CLU, Benefits Consultant
Social Security offers several types of monthly benefits for a
disabled person, Social Security Disability Insurance (SSDI),
Supplemental Security Income (SSI) as well as disability benefits for disabled
widows, children, and adult children disabled since
childhood. While each program has its own requirements for
non-medical eligibility, they all use the same definition of total disability
and the same method to determine if a person is "disabled enough" to be eligible
for disability benefits.
Under Social Security a person is considered disabled if: (1) Due to
a medical condition he/she is unable to perform the tasks of a job for which
he/she is suited, AND (2) That condition either has or will last for at least
twelve months or is expected to result in death.
Well over 50% of the initial applications for disability benefits are
denied, not because the disability definition is that difficult to
meet, but primarily because the applicant didn't understand the
disability determination process and didn't give Social Security
the information they needed to award benefits.
The problem of being denied Social Security benefits appears to
affect people with HCV even more, for several additional reasons:
To Social Security, HCV is a relatively new disabling condition and
they really haven't develop an organized approach to reviewing
HCV claims;
The symptoms of HCV can vary from none at all to completely
debilitating, so the diagnosis of HCV alone doesn't have much
impact in determining disability; and,
Many of the most common symptoms of HCV are "subjective" in
that they can't be readily measured in a laboratory test. Examples are
fatigue, headaches, memory loss, and depression. Therefore, medical records
alone often don't adequately describe the functional problems the applicant has
trying to work.
A person dealing with HCV rarely suddenly awakens one day to find himself or
herself unable to continue working. Typically, it's a
gradually deteriorating ability to work. Work becomes more and more difficult;
finding the energy to work is more and more
time-consuming. Some reach the point where they only work and spend the
remainder of their time in bed trying to regain enough strength to return to
work.
If you believe that the time to apply for Social Security Disability
is approaching, especially in the next few months there are two
things you can do before stopping work and applying that can greatly increase
your chances of getting your claim approved the first time around:
(1) Learn how Social Security processes a claim for disability; and, (2)
Assemble and review the "medical evidence" which they will
use to determine if you are disabled by their definition.
Learn How Social Security Processes a Claim for Disability
Social Security has put a lot of information about the disability
process on their website at www.ssa.gov.
For example, in examining a disability claim there are five questions that a
Disability Analyst seeks the answers to:
1. Are you working?
2. Is there a medical problem that impacts your ability to
work to any degree?
3. Is your condition found in the Listing of Impairments?
(more on that below)
4. Can you do the work you did previously?
5. Can you do any other type of work?
To be eligible for benefits, the answer to #1 must be "No,"
and the answer to #2 must be "Yes."
If the answer to #3 is "Yes," your claim will be approved. If
not, then both #4 and #5 must be "No."
To facilitate the process and to maintain some uniformity throughout the
country, Social Security publishes a book called, Disability Evaluation Under
Social Security, or "The Blue Book" which includes a Listing of Impairments. If
your medical condition is listed in that Listing of Impairments, and it meets
the criteria given, then your claim is routinely approved.
The Listing, unfortunately, does not directly deal with Hepatitis C,
although there is a listing for Chronic Liver Disease that includes
chronic active hepatitis.
However, because the symptoms can vary substantially, they also
include some guidelines on how severe the condition must be:
"5.05 Chronic liver disease (e.g., portal, postnecrotic,
or biliary cirrhosis; chronic active hepatitis; Wilson's disease). With:
Esophageal Varices (demonstrated by endoscopy or other appropriate medically
acceptable imaging) with a documented history of massive hemorrhage attributable
to these varices. Consider under disability for 3 years following the last
massive hemorrhage; thereafter, evaluate the residual impairment; or
Performance of a shunt operation for esophageal varices. Consider
under a disability for 3 years following surgery; thereafter,
evaluate the residual impairment; or
Serum bilirubin of 2.5 mg. per deciliter (100 ml.) or greater
persisting on repeated examinations for at least 5 months; or
Ascites, not attributable to other causes, recurrent or persisting
for at least 5 months, demonstrated by abdominal paracentesis or
associated with persistent hypoalbuminemia of 3.0 gm. per deciliter
(100 ml.) or less; or
Hepatic encephalopathy. Evaluate under the criteria in Listing 12.02; or
Confirmation of chronic liver disease by liver biopsy (obtained
independent of Social Security disability evaluation) and one of the
following:
Ascites not attributable to other causes, recurrent or persisting
for at least 3 months, demonstrated by abdominal paracentesis or
associated with persistent hypoalbuminemia of 3.0 gm. per deciliter
(100 ml.) or less; or
Serum bilirubin of 2.5 mg. per deciliter (100 ml.) or greater on
repeated examinations for at least 3 months; or
Hepatic cell necrosis or inflammation, persisting for at least 3
months, documented by repeated abnormalities of prothrombin time and enzymes
indicative of hepatic dysfunction."
http://www.ssa.gov/disability/professionals/bluebo
ok/AdultListings.htm
If your medical condition meets one of these criteria, your claim
should be approved. However, it will help if your physician states
the condition in a letter to Social Security, using terms and results as shown
in the Listing.
If your condition does not meet any of these criteria, all is not
lost. It is still possible to have your claim approved if the
symptoms you exhibit are as severe as one of the listings. If your symptoms
clearly show that the answers to questions #4 & 5 are both no, your claim will
also be approved.
Usually, however, more medical evidence will be required to get the
claim accepted. In that case, you should make sure you submit all the medical
evidence that you can with the application.
Assemble and Review Your Medical Evidence
The most important evidence in determining disability is the records of your
medical providers. This could be more than the records of
your primary care physician and specialist. It may also include the
records of your therapist, chiropractor, acupuncturist and other medical
practitioner. "Non-medical establishment" providers won't
carry the weight of "regular" doctors, but they can support your claim by
documenting your symptoms and your efforts to relieve them.
Disability determination focuses on your symptoms and how they
prevent you from working so it is a good idea to make sure your physicians enter
your symptoms into the record with each visit, even if it is repetitive.
To greatly speed up processing time, it is also recommended that you take copies
of your medical records when you go to your initial
interview with Social Security.
While the medical records of your providers are the primary source of evidence
in reviewing your claim, there are other documents and
records that can help your claim as well.
These include:
Questionnaires - Once you apply for disability benefits, the
Disability Analyst will send you questionnaires to get specific
information. They may be about Pain, Fatigue, your daily activities,
or other conditions or symptoms. These questionnaires are your
opportunity to transform the medical data from your physicians into
actual descriptions of the problems your condition cause you when
working and in your daily routine. You should not skimp on these or rush through
them quickly. Take your time, add extra sheets of paper, well-labeled, and
thoroughly describe in detail exactly how your symptoms impact your routine.
Letters from Physicians - Ask each of your doctors to write a
thorough summary of your condition. They should focus on relating the medical
conditions and test results to the symptoms you are experiencing. To adequately
do the job, each letter should be several pages long, not just a couple of
paragraphs
Third Party Testimony - These are letters from friends, family,
or co-workers that describe their observations of your problems trying to
function. These should be anecdotes and descriptions of what they have observed
in your performance. One of the best is a copy of a "write-up" by your
supervisor on your deteriorating
performance from your personnel file. Not everyone will have one of these as
many people work that much harder to make sure their performance doesn't
deteriorate.
Letters from a spouse or housemate co-worker on how your activities and
abilities have changed due to your condition are good also. A description
through anecdotes of how your ability to function has deteriorated should be
their goal. While these alone won't get your claim approved, they do help
provide a good picture of how your medical condition affects your activities.
Symptom Diary - This can be an especially helpful tool when the
symptoms are primarily subjective. Psychologically it is not fun to
do, but it can help confirm the impact of the symptoms on your
activities. A symptom diary is simply a daily log, in which you enter
the symptoms you experienced during the day, their severity including how long
they lasted, and their impact on your daily activities such as requiring you to
rest, cancel planned appointments, etc.
This seems like a lot of work just to get benefits that you deserve,
but, remember, Social Security is so big that they can't be bothered
with "what's fair" or "what you deserve." You need to know their rules and "play
the game" by them. Making the effort with the
initial application can avoid having to drag through a year or more of appeals
and sharing your award with an attorney, which will save you time, money, and
lots of stress.
[Jacques Chambers, CLU, and his company, Chambers Benefits
Consulting, have over 35 years of experience in health, life and disability
insurance and Social Security disability benefits. For the past twelve years, he
has been assisting people with their rights, problems, and other issues
concerning benefits and disability. He can be reached at
jacques@... or through his website at:
http://www.helpwithbenefits.com
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/13/2003

Donating Part of Lung Possible, May Cut Wait List

2008-11-24 22:27:25

Donating Part of Lung Possible, May Cut Wait List
Tue Jun 3, 2003
By Alicia Ault
WASHINGTON (Reuters Health) - Portions of lungs transplanted from living donors
function as well in the recipient as whole cadaver lungs, and should be
considered as an option for those waiting for an organ, a surgeon reported here
Monday.
Dr. Michael Bowdish of the University of Southern California said that data
collected at his transplant center support more widespread use of partial lungs
from living donors.
There are 3,892 Americans on the waiting list for a lung, according to the
United Network for Organ Sharing (UNOS). But there are only about 800 to 1,000
lungs transplanted each year from cadavers, and only 20 or fewer from living
donors.
Bowdish said that surgeons have been reluctant to use partial lungs, or lobes,
out of concern that they might not function as well as whole lungs. Most lung
lobes are transplanted into patients with cystic fibrosis, and they usually come
from one or more living donors.
In his study, the surgeon looked at survival and lung function in patients who
received lung transplants from 1993 to 2002 and survived longer than 90 days.
Fifty-nine received a lobe, and 43 received two cadaver lungs.
Ninety-five percent of the living donor recipients had cystic fibrosis, while
the cadaveric recipients had other life-threatening lung diseases such as
primary pulmonary hypertension or chronic obstructive pulmonary disease.
After three years, there was no statistical difference in survival, and both
groups had similar levels of exercise tolerance and improvement in pulmonary
function, said Bowdish. Both groups also had the same rates and types of
infection.
"These results clearly demonstrate that smaller lobar grafts provide comparable
function," said Bowdish, who presented his data at the American Transplant
Congress, the largest gathering of transplant surgeons and researchers in the
U.S.
He urged transplant centers to consider living lobar donation more often.

Hello From Palm Springs CA

2008-11-24 20:23:08

Hello Everyone,
I want to CONGRATULATE CHERIE! On clearing the virus.
And I want to thank my dear sweet friend Pam for this wonderful group.
Sending prayers and healing light to everyone.
Your Hep Sister,
Lynn

Re: [HepCingles2] Digest Number 1439

2008-11-24 14:00:48

Hi Deb - My Genotype is 2, but I don't know A or B, just had the test done
not long ago. My only known risk factor tells me I probably got it in 1974
during a 4 month stint of shared needles using heroin and lots of other
stuff in Berkeley and Santa Cruz Mountains (Ben Lomond) - which puts it at
possibly being in me for 32 years, but there's no way of knowing that I got
it back then; I could've gotten it with cocaine use up to 1986 - so who
knows? Best of luck to you! Corinne AND GOOD NEWS for YOU, BAYLA!!!!

Tee

2008-11-24 10:26:08

Hey Tee........ Wythe told me you had been in the chat but that you were
growing sleepy! I was really late....... I had gone out to dinner and
didn't get there until about 11P. I am sure we will find each other next
Saturday if not sooner in some other chat :-) Take care!
Peace and Love,
Pam
Dogs come when they're called. Cats take a message and get back to you. --
Missy Dizick

Hemachromatosis - the Celtic Curse

2008-11-23 19:33:26

http://www.americanhs.org/celtic.htm
http://www.rte.ie/tv/thehealthshow/thisweek.html
http://www.dailynebraskan.com/vnews/display.v/ART/2000/03/10/38c86e889
http://www.methodisthealth.com/blood/hemachro.htm
Hemochromatosis
What is hemochromatosis?
Hemochromatosis, also called iron overload disease, is the most common
genetic disorder in the US. It is a metabolic disorder that causes increased
absorption of iron, which is deposited in the body tissues and organs. The
iron accumulates in the body where it may become toxic and cause damage.
What causes hemochromatosis?
Hemochromatosis is a hereditary disease, often most prevalent among people
of Scottish, Irish, or English descent.
What are the symptoms of hemochromatosis?
The following are the most common symptoms for hemochromatosis, however,
each individual may experience symptoms differently:
lethargy and weakness
irritability
depression
joint pain
bronze or yellowish skin color
loss of body hair
impotence in men
amenorrhea in women
Untreated or severe hemochromatosis may lead to:
abnormal heart rhythm
congestive heart failure
enlarged liver
enlarged spleen
diabetes
The symptoms of hemochromatosis may resemble other blood disorders or
medical problems. Consult your physician for a diagnosis.
How is hemochromatosis diagnosed?
Hemochromatosis is usually discovered during a medical examination through a
routine blood test. In addition to a complete medical history and physical
examination, diagnostic procedures for hemochromatosis may include:
transferrin saturation test (TS)
liver biopsy
Treatment for hemochromatosis:
Specific treatment for hemochromatosis will be determined by your
physician(s) based on:
your overall health and medical history
extent of the disease
your tolerance for specific medications, procedures, or therapies
expectations for the course of the disease
your opinion or preference
Treatment may include:
periodic phlebotomy (removing blood from the body)
diet modification
treatment of the resulting diseases or conditions
I know several people that have this Tricia and all have phlebotomies from
time to time. I was tested for it when my iron got into the 500's for
awhile (normal is more like 60ish) It got better for me after treatment
(the only thing that got better LOL) Since I have a high H&H (Hemoglobin
and Hematocrit) I usually have to have a pint taken out 2 or 3 times a year
anyway. I am sure that helps keep the iron load low too :-) It was way
to high on my liver biopsy back in 1997 as well. Have you been tested? I
know when I was tested for Alpha 1 Antitrypsin I was in a panic for the week
I was waiting for the results. When I went on line and read about it
absolutely everything fit me to a tee......... even the scandanavian
heritage (I am Swedish) Anyway, I hope you don't have to deal with this
too........ how are your iron levels? Take care of yourself!
Peace and Love,
Pam
Dogs come when they're called. Cats take a message and get back to you. --
Missy Dizick

Re: [HepCingles2] Racial Makeup of Patients Determines Response Rates to HCV Treatments

2008-11-23 14:29:33

Pam this report reminded me of something I read called the Celtic Curse. For
some reason families pure celt seem to get the disease at high rates. Also I
read that 1b (mine) is considered an European strain. Have you ever heard of
these as factors. I had the Celtic Curse on old puter but of course lost
now. It is available at one of celt sites or your mainstay google will
probably bring it right up. My doctor said with my mom and her sister being
pure celts and both dying of liver cancer that he is inclined to believe
genetics can play some part in who is more vulnerable or less likely to
retain remission. Put your little blond head to work again hey? Love ya,
Tricia

Re: Saturday night chat

2008-11-23 13:47:36

Hey Pam
Sorry I missed you Saturday . The new antidepressan I have started
takeing knock me out about 40 mins after I take them.. Hope to talk
to you soon..
Tee

Is this the Bill we need?

2008-11-23 02:59:16

Finally, a bill that addresses Hepatitis C, we are all breathing a
collective sigh of relief. But, is it the bill we need? Though Bill
1143, is a step in the right direction, it is flawed and needs to be
rectified before the Hepatitis C Community should support it.
**********************************************************
PRESS RELEASE: Hepatitis C Weekend for Awareness
Consensus Statement
HEPATITIS C MOVEMENT FOR AWARENESS
HMAwareness@...
110 Glover Circle, Staunton, Virginia 244401
TEL: 540-248-4994
May 25, 2003
Grass roots Hepatitis C activists, from across the United States
and Canada, gathered in Washington, DC from May 21 through
May 25, 2003 for the second annual Weekend of Awareness.
Approximately 100 leaders of support groups, veteran's
organizations, Internet chat rooms, counselors, political action
committees, and others gathered at the Holiday Inn Downtown
where they received reports from other activists, as well as
professionals, on the state of Hepatitis C in the United States,
Canada, North America, and rest of the world.
Hepatitis C (HCV) is a virus that is transmitted by blood to blood
contact that is now four more times more prevalent than
HIV/AIDS. It is estimated that up to 5 million Americans are
infected with the deadly virus (US Census Bureau, July 31,
2001).
HCV is the leading cause for liver transplants in the United
States and up to 10,000 Americans will die due to complication
from the virus this year.
CONSENSUS OF THE 2003 WEEKEND FOR AWARENESS:
Government, at all levels in the United States, is doing far too
little to combat HCV. Conservative estimates place the costs of
lost productivity and medical care arising from chronic Hepatitis
C in the United States at over $600 Million annually and such
costs are expected to increase in the absence of expanded
prevention and treatment efforts.
Legislation was filed in the United States Senate on May 22,
2003 "to direct the Secretary of Health and Human Services to
establish, promote, and support a comprehensive prevention,
research, and medical management referral program for
Hepatitis C infection."
Senate Bill 1143 (the Hepatitis C Epidemic Control and
Prevention Act) is sponsored by Senator Edward M. Kennedy, of
Massachusetts, and Senator Kay Bailey Hutchison, of Texas.
While the Hepatitis C Movement for Awareness enthusiastically
supports most provisions of 1143, we feel there are several
provisions in the bill that raise serious questions. Among them
is a provision that would link Hepatitis C with HIV/AIDS and
Sexually Transmitted Disease (STD) programs. Hepatitis C
must be addressed separately and apart from HIV and must not
be paired with HIV and STD. It is primarily a blood-borne virus
and rarely transmitted through sexual activities.
In the bill, the recommendations and guidelines of the National
Hepatitis C Prevention Strategy
"provide a framework for Hepatitis C prevention, control,
research, and medical management referral programs."
However, the National Hepatitis C Prevention Strategy states that
"the most effective means to prevent HCV infection and its
consequences is to integrate Hepatitis C prevention activities
into existing clinical services and public health programs, such
as those for the prevention and treatment of human
immunodeficiency virus (HIV)/Acquired Immune Deficiency
Syndrome (AIDS), sexually transmitted diseases (STDs) and
drug use."
Additionally, guidelines for allocating grants and funding to
organizations and entities professing to provide "education,"
"training," "outreach" and other services fail to define the
qualifications those organizations and entities must meet to be
eligible for funding through this Act. Instead, the guidelines are
proposed to be set up by the Secretary of Health and Human
Services (HHS). We feel those qualifications and guidelines
must be defined in 1143 and the Secretary should be
responsible for enforcement procedures.
The $90 million being proposed by this bill must be spent in the
most efficient and effective manner to make sure the Act serves
people with Hepatitis C. The Act would allow the Secretary of
HHS to "award grants to, or enter into contracts or cooperative
agreements with states, political subdivisions of states, Indian
tribes, or nonprofit entities that have special expertise relating to
HCV, to carry out activities..."
"To be eligible for a grant, contract, or cooperative agreement...,
an entity shall prepare and submit to the Secretary an application
in such time, in such manner, and containing such information
as the Secretary may require," the bill states.
The Hepatitis C Movement for Awareness, after reviewing the
proposed Act, concluded that the guidelines for all applications
must be clearly defined in the legislation, and voted on by
Members of Congress. Defining these guidelines must not be
left up to bureaucrats in HHS.
We also have serious problems with the proposed make-up of a
proposed "Liver Research Advisory Board." In our opinion, as
currently being proposed, there would be too little representation
from the grass roots HCV community and private medical sector.
Overall, however, we support Senate Bill 1143, but feel sponsors
should have reached out to a broader base of People with
Hepatitis C in the United States for input on developing the
legislation. There are, unfortunately, several provisions in the bill
that we feel must be amended before we can recommend that
our elected representatives in the108th Congress support 1143.
We have asked several Members of Congress, including United
States Representative Sheila Jackson Lee and United States
Representative Chris Bell, to seek a study or investigation of
Hepatitis C by the General Accounting Office. This study would
help Congress better understand the Hepatitis C virus and allow
lawmakers to develop effective and cost effective legislation to
"combat." There is no reason that plan cannot be achieved
through amending Senate Bill 1143. The Hepatitis C Movement
for Awareness asks that all action on 1143 be put on hold
pending the GAO study.
FOOTNOTE: A Hepatitis C Movement for Awareness Summit on
Senate Bill 1143 is being arranged to be held in Washington, DC
in coming weeks. The Summit will provide sponsors and
supporters of the bill tan opportunity to meet with grass roots
HCV activists and discuss the bill. It will also give lawmakers an
opportunity to hear from grass roots activists as opposed to
professional lobbyists and government bureaucrats. We urge all
parties involved to contact representatives of Hepatitis C
Movement for Awareness so that inclusion rather than exclusion
can become part of the process.

Re: [HepCingles2] and the answere is

2008-11-23 02:16:02

Congrats from a fellow G3 about to go on a search and destroy mission
Bayla <bgumins@...
w/a genotype 3..staying clear I'm told after tx at the six month mark, its as
good as GONE!!!
~Bayla~
"C" It! Treat It! Beat It!!
http://hometown.aol.com/nydragonslayer/
http://www.healsofnfl.bravehost.com/
http://hepcaware.org/

InterMune Announces Interim Data Showing High Early Virologic Response To Infergen in Peg-Interferon Non-Responders With Chronic Hepatitis C

2008-11-22 12:43:57

InterMune Announces Interim Data Showing High Early Virologic Response To
Infergen in Peg-Interferon Non-Responders With Chronic Hepatitis C
24-week Data Supports Potential Antiviral Efficacy, Tolerability In
Difficult-to-Treat Patients
ORLANDO, Fla. and BRISBANE, Calif., May 19 /PRNewswire-FirstCall --
InterMune, Inc. (Nasdaq: ITMN) announced today that interim 24-week data showing
high early virologic response rates in a clinical trial of daily dosing and
induction dosing regimens of Infergen(R) (interferon alfacon-1) in chronic
hepatitis C patients non-responsive to pegylated interferon and ribavirin
combination therapy (non-responders) were presented at the Digestive Disease
Week (DDW) 2003 conference in Orlando, Florida.
Researchers reported the interim data showed that more than half (52%) of
the non-responders subsequently responded to treatment, which included 27
micrograms daily interferon alfacon-1 monotherapy for 4 weeks, followed by 20
weeks of daily combination therapy with lower doses of interferon alfacon-1 plus
ribavirin. The patients in the trial will continue on combination therapy for an
additional 24 to 64 weeks.
"These interim data indicate the potential of interferon alfacon-1 to
effectively clear the hepatitis C virus in these difficult-to-treat non-
responders, who were predominantly patients with genotype 1 HCV and high viral
load," said Dr. Stephan Kaiser of the University Hospital of Tubingen, Germany,
lead principal investigator of the trial, who presented the data at DDW. "In
addition, both the daily dosing and induction dosing regimens were moderately
well tolerated. If the encouraging early antiviral response rates seen in this
interim analysis translate into correspondingly strong sustained antiviral
response rates, interferon alfacon-1 may become the foundation for optimal
management of these non-responding patients."
"Over 50% of HCV patients fail standard-of-care treatment with pegylated
interferons and ribavirin, and the growth of this patient population is expected
to outpace that of treatment-naive, chronic hepatitis C patients by the end of
the decade. Further, past clinical studies on the use of the combination of
pegylated interferons and ribavirin for re-treatment of non-responders to
standard-of-care treatment have demonstrated only limited therapeutic efficacy,"
said James E. Pennington, M.D., InterMune's Executive Vice President of Medical
and Scientific Affairs. "These interim data, which corroborate previous studies
showing interferon alfacon-1 provides a high antiviral response in
difficult-to-treat non-responders, could be very important in helping to meet
this growing unmet medical need and large market opportunity. Because the
interim data show both high and early virologic response, it is our hope that
these patients will attain a sustained virologic response."
Results Review
A randomized, open-label trial was conducted in 50 chronic hepatitis C
patients who were non-responders to prior combination therapy with pegylated
interferon and ribavirin. Two-thirds of the patients in the trial had failed
treatment with pegylated interferon alpha-2b, and one-third of the patients had
failed therapy with pegylated interferon alpha-2a. More than 90% of the patients
in the trial were infected with HCV of genotype 1 or 4, which are the most
difficult to treat genotypes. Over 70% of the patients in the trial had high
baseline levels of HCV RNA (viral load
Patients on the daily dosing regimen received 9 micrograms interferon
alfacon-1 daily for 4 weeks, followed by a daily combination of 9 micrograms
interferon alfacon-1 plus ribavirin for 20 weeks. Patients on the induction
dosing regimen received 27 micrograms interferon alfacon-1 daily for 4 weeks,
then a daily combination of 18 micrograms interferon alfacon-1 plus ribavirin
for 12 weeks, followed by a daily combination of 9 micrograms interferon
alfacon-1 plus ribavirin for the next 8 weeks. The patients in the trial will
continue on combination therapy for an additional 24 to 64 weeks, depending on
progress and whether they were assigned to the daily dosing or induction dosing
regimen.
The efficacy endpoints for this trial include: (a) the effects of initial
treatment with interferon alfacon-1 on the level of HCV RNA in serum; and (b)
the ability of the combination of interferon alfacon-1 and ribavirin to render
the level of HCV RNA in serum undetectable at 24 weeks after the cessation of
therapy. Antiviral efficacy was evaluated by PCR measurement of concentrations
of HCV RNA in serum. The interim analysis consisted of examination of HCV viral
load at 8 and 24 weeks and evaluation of safety data.
At week 8, an antiviral response consisting of a negative PCR result
(i.e., undetectable HCV RNA) in serum was observed in 20% (6/30) and 27% (8/30)
of patients treated with the daily dosing and induction dosing regimen,
respectively. At week 24, an antiviral response consisting of HCV RNA
undetectable by PCR in serum samples was observed in 40% (10/25) and 52% (14/25)
of patients treated with the daily dosing and induction dosing regimen,
respectively.
Both the daily dosing and induction dosing regimens of interferon alfacon-
1 were found to be safe and moderately well tolerated. Adverse events were
consistent with past experience in clinical trials and included myalgia, fatigue
and headache. The laboratory abnormalities observed in the first 24 weeks of
therapy were also consistent with those observed in past Infergen clinical
trials, with no reports of grade 4 neutropenia and grade 3/4 thrombocytopenia
reported in only one patient.
About Chronic Hepatitis C
Over 4 million individuals in the United States have been exposed to the
hepatitis C virus. More than 200,000 patients in the United States are treated
annually for hepatitis C infection. The prevalence of chronic hepatitis C, a
serious disease, is increasing.
About Infergen (R) (interferon alfacon-1)
Infergen(R) is a bio-optimized type 1 interferon alpha indicated for
treatment of adult patients with chronic HCV infections. Infergen(R) is the only
interferon alpha with data in the label regarding use in patients following
relapse or non-response to treatment with certain previous treatments. The most
common side effects are flu-like symptoms (i.e. headache, fatigue, fever,
myalgia, and rigors). Physicians and patients can obtain additional prescribing
information regarding Infergen(R), including the product's safety profile, by
visiting http://www.infergen.com, including the black box warning for all
interferon alphas regarding psychiatric, autoimmune, ischemic and infectious
disorders.
About InterMune
InterMune is a commercially driven biopharmaceutical company focused on
the marketing, development and applied research of life-saving therapies for
pulmonary, infectious and hepatic diseases. For additional information about
InterMune, please visit http://www.intermune.com .
Except for the historical information contained herein, this press release
contains certain forward-looking statements that involve risks and
uncertainties, including without limitation the statements indicating that: (i)
these interim data indicate the potential of interferon alfacon-1 to effectively
clear the hepatitis C virus in these difficult-to-treat, non- responders, who
were predominantly patients with genotype 1 HCV and high viral load; (ii) if the
encouraging early antiviral response rates seen in this interim analysis
translate into correspondingly strong sustained antiviral response rates,
interferon alfacon-1 may become the foundation for optimal management of these
non-responding patients; (iii) growth in the population of patients who are
non-responsive to standard-of-care treatment is expected to outpace that of
treatment-naive, chronic hepatitis C patients by the end of the decade; (iv)
these interim data, which corroborate previous studies showing interferon
alfacon-1 provides a high antiviral response in difficult- to-treat
non-responders, could be very important in helping to meet this growing unmet
medical need and large market opportunity; and (v) because the interim data show
both high and early virologic response, it is hoped these patients will attain a
sustained virologic response. Factors that could cause or contribute to such
differences include, but are not limited to those discussed in detail under the
heading "Risk Factors" and the other risks and factors discussed in InterMune's
10-Q report filed with the SEC on May 14, 2003, and other periodic reports
(i.e., 10-K and 8-K) filed with the SEC, which are incorporated herein by
reference. The risks and other factors that follow, concerning the above
forward-looking statements in this press release, should be considered only in
connection with the fully discussed risks and other factors discussed in detail
in the 10-Q report and InterMune's other periodic reports filed with the SEC.
The forward-looking statements above are subject to the risks and uncertainties
that include, without limitation, those associated with: (a) drawing any
clinical, medical or other meaning or conclusion from the interim data,
forward-looking statements and hypotheses; (b) obtaining data from other
clinical trials of Infergen for the treatment of HCV non-responders; (c) the
clinical development process; (d) InterMune's ability to obtain, maintain and
enforce patents and other intellectual property; (e) significant regulatory,
supply, intellectual property and competitive barriers to entry; and/or (f) the
risks and other factors discussed in the 10-Q report.
SOURCE InterMune, Inc.
CONTACT: investors, Myesha Edwards of InterMune, Inc., +1-415-466-2242, or
medwards@...; or media, Jim Weiss, +1-415-362-5018, or
jim@..., for InterMune, Inc.
Web site: http://www.intermune.com
(ITMN)
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=ITMN&script=410&layout=-6\
&item_id=414591
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/14/2003

The Impact of Diabetes on Chronic Hepatitis C

2008-11-22 09:49:02

The Impact of Diabetes on Chronic Hepatitis C
Data from the NHANES III trial has suggested that type 2 diabetes (DM) is more
prevalent in patients with chronic hepatitis C (Ann Intern Med 2000;133:592-9).
In this study, researchers sought to describe clinical features of patients with
chronic hepatitis C (CHC) and DM and to determine the impact of DM on the
natural history of CHC and its treatment.
The researchers performed a retrospective case control study of 60 patients with
CHC and DM and 60 controls with HCV alone who were matched for age, gender,
race, genotype, and treatment status. Comparisons were made of BMI, liver
histology, fibrosis progression rates, and response to antiviral therapy. We
also assessed the effect of antiviral therapy on DM management.
Although there were more overweight patients (BMI
group (83% vs. 53%, p=0.02), the average BMI was similar in the 2 groups (28.3
vs. 26.1, p= 0.09). Forty-nine of the diabetics and 53 controls had liver
biopsy. Patients with CHC and DM were more likely to have advanced fibrosis on
liver biopsy (Metavir stage 3&4) than controls (61% vs. 28%, p= 0.04).
Steatosis was also more common in the CHC and DM group when compared with
controls (65% vs. 40%, p=0.8) although this difference was not statistically
significant. The severity of steatosis was similar in both groups. Of the 79
patients with a known estimated duration of infection, CHC and DM patients had
significantly higher overall fibrosis progression rates than controls. Even in
the absence of steatosis, patients with CHC and DM had higher fibrosis
progression rates than patients without DM.
CHC and DM patients had lower overall SVR rates to CHC treatment than controls,
although this difference disappeared when response rates to PEGIFN/RBV were
looked at alone (33% vs. 31%).
While on CHC treatment, 37% (13/35) of CHC and DM patients required changes in
their DM management. These changes included new diagnosis of DM (n=3), the
addition of a new oral hypoglycemic agent (OHA; n=3), an increase in OHA or
insulin dose (n=5), and change from OHA to insulin while on therapy (n=2).
The authors concluded the following:
(1) Patients with CHC and DM are heavier than those without DM;
(2) Patients with DM have more steatosis and significantly more fibrosis
on liver biopsy when compared with controls;
(3) Patients with DM have significantly higher fibrosis progression rates
even in the absence of steatosis;
(4) Changes in DM management while on CHC treatment are common;
(5) Further studies on this population are warranted.
05/30/03
Reference
F Ahmed and others. Impact of Diabetes on Chronic Hepatitis C. Abstract M1416
(poster). Abstracts of Digestive Disease Week 2003. May 17-22, 2003. Orlando,
FL, USA
http://www.hivandhepatitis.com/hep_c/news/053003f.html
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/14/2003

Neutropenia Associated with HCV Therapy May Not Be Associated with Serious Adverse Events

2008-11-22 07:34:28

Neutropenia Associated with HCV Therapy May Not Be Associated with Serious
Adverse Events
By Brian Boyle, MD
Neutropenia is a common event in patients treated with pegylated interferon and
ribavirin; however, the clinical importance of the neutropenia is uncertain.
In a study presented at Digestive Disease Week 2003 (DDW), investigators
evaluated whether the neutropenia induced in patients treated with pegylated
interferon and ribavirin led to any clinically serious adverse events, such as
infections.
The investigators obtained data regarding adverse events from the WIN-R Trial, a
study that enrolled 4,243 patients and compared fixed (800mg) versus weight
based (800-1400mg) daily dosing of Rebetol (ribavirin) in combination with
PEG-Intron (pegylated interferon alfa-2b). The investigators reviewed the
adverse event data collected throughout the 48 weeks of therapy.
The investigators found that 30 (0.7%) of the patients developed infectious
serious adverse events while on the PEG-Intron + Rebetol therapy. The infections
included 10 patients with pneumonia, 3 with urinary tract infections, 3 with
cellulitis, 2 with upper respiratory tract infections, 4 with an abscess, and
one each with cat scratch disease, salmonella colitis, furuncle, meningitis,
appendicitis with perforation, tibial hardware infection, bacteremia, and
invasive C. jejuni diarrhea.
Of these patients, 24 received antibiotics, 27 were hospitalized, and 7 required
surgical intervention. One patient died of pneumonia.
Examining the absolute neutrophil counts, the investigators found that the ANC
fell below 1000 at some point in 14 of 25 (56%) of the patients that developed a
serious infection. Further, they found that overall mean nadir ANCs in patients
with a serious adverse event and all treated patients were not significantly
different, 1198 and 1318, respectively (p=0.46).
Finally, the mean nadir ANC for the serious adverse event patients also did not
significantly differ from that of the rest of the patients and the proportion of
patients who developed an ANC <750 were similar in both groups (20%).
Based upon these data the authors conclude, "(1) Patients who develop serious
infections while on combination therapy with pegylated interferon alfa-2b and
ribavirin do not have significantly lower mean nadir ANCs. (2) Infectious
[serious adverse events] generally did not occur at the time of nadir ANC. (3)
Criteria and utility for dose reduction of peginterferon and the use of
granulocyte stimulating factor to treat neutropenia require further assessment."
05/28/03
Reference
F Ahmed and others. Clinical Significance of Pegylated Interferon Induced
Neutropenia: Results from the WIN-R Trial. Abstract 213 (oral). Abstracts of
Digestive Disease Week 2003. May 17-22. Orlando, FL, USA.
http://www.hivandhepatitis.com/hep_c/news/052803g.html
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/14/2003

A Cryocrit Cutoff of 2% Best Predicts Outcome After Liver Transplantation for Hepatitis C

2008-11-22 01:03:55

A Cryocrit Cutoff of 2% Best Predicts Outcome After Liver Transplantation for
Hepatitis C
The rapid recurrence of severe hepatitis C viral (HCV) hepatitis after liver
transplantation remains a major problem. Currently, there are no known
predictors of rapid recurrence of HCV disease.
Because of the poor outcome observed in patients with cryoglobulinemia (cryo),
we have evaluated the effect of cryo on graft survival, severe activity, and
severe fibrosis after transplantation and have looked at various cutoffs for
defining a cryocrit as positive.
Using their longitudinal database, researchers analyzed survival for all
recipients of liver transplants for cirrhosis due to HCV (1991 onward) based on
the presence or absence of cryo.
All liver transplant biopsies were analyzed (in a blinded fashion) and activity
and fibrosis were graded using the Ludwigs scale. Severe activity was defined as
moderate (or worse activity, including fibrosing cholestatic hepatitis) and
severe fibrosis was defined as bridging fibrosis or cirrhosis.
Graft survival, and survival until the onset of severe activity and fibrosis
were determined using Kaplan Meier estimates. Survival analysis was performed
for the entire population and after excluding patients who died or lost their
grafts for reasons other than recurrent HCV.
The log rank test was used to compare survival and Cox multivariate analysis was
used to determine relative risks (RR).
Results are noted in the table below:
Graft Survival
Severe Activity
Severe Fibrosis
Maximum cryocrit
RR
p
RR
p
RR
p
Trace
1.6
0.3
2.4
0.007
2.1
0.04
1.7
0.2
2.6
0.003
2.3
0.02
1.8
0.2
2.4
0.006
2.3
0.02
3.2
0.01
4.0
0.0001
3.6
0.002
The results were stronger when recipients who lost their allografts from
causes other than recurrent HCV were excluded from the analysis.
Conclusions: Liver transplant recipients with cryoglobulinemia are at greater
risk for graft loss, severe early activity, and severe early fibrosis. Using a
cryocrit cutoff of 2% increases the apparent deleterious effect of
cryoglobulinemia and provides the strongest indication of those at increased
risk.
05/30/03
Reference
SC Rayhill and others. A Cryocrit Cutoff of 2% Best Predicts Outcome After Liver
Transplantation for Hepatitis C. Abstract 52 (poster). Abstracts of Digestive
Disease Week 2003. May 17-22, 2003. Orlando, FL, USA.
http://www.hivandhepatitis.com/hep_c/news/053003g.html
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/14/2003

Racial Makeup of Patients Determines Response Rates to HCV Treatments

2008-11-21 18:19:50

Racial Makeup of Patients Determines Response Rates to HCV Treatments
Researchers have noted in their practice that Afro-American patients treated
with Interferon/Ribavarin or PEG/Ribavarin combination therapy seem to have
sustained clearance of hepatitis C virus at a lower rate than Caucasian
patients.
In this study, the investigators sought to determine the viral clearance rate of
Hepatitis C virus in patients with chronic hepatitis C treated with
Interferon/Ribavirin or PEG/Ribavirin combination based on racial makeup.
This study is a retrospective review of 287 patients with documented hepatitis C
(PCR positive) who were treated with Interferon/Ribavirin or PEG/Ribavirin
combination therapy. There were 170 Caucasians, 32 Hispanic and 85 Afro-American
patients. The percentage of patients with sustained clearance of the virus for
six months post-treatment was calculated for each racial group.
7% of Afro-American patients cleared the virus. 28% of Hispanic patients cleared
the virus. 42% of Caucasian patients cleared the virus. The difference in
clearance rates of the virus between Afro-Americans and Caucasians was highly
significant with the p < 0.0001.
The difference in clearance rates between Caucasians and Hispanics was
significant with p < 0.04.
The difference in clearance rates between Afro-Americans and Hispanics was
significant with p < 0.02.
Conclusion: Afro-American patients with chronic hepatitis C showed a
significantly lower sustained clearance rate to Interferon/Ribavirin or
PEG/Ribavirin combination therapy than Caucasian or Hispanic patients.
05/30/03
Reference
BJ Levitt and others. Differential Response Rates to Clearance of Hepatitis C
Virus in Chronic Hepatitis C, Based on Racial Makeup of Patients Treated With
Interferon/Ribavirin (I/R) or Peg/Ribavirin (Peg/R) Combination. Abstract T1286
(poster). Abstracts of Digestive Disease Week 2003. May 17-22, 2003. Orlando,
FL, USA.
http://www.hivandhepatitis.com/hep_c/news/053003d.html
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/14/2003

Daily Interferon Plus Ribavirin Is More Effective Than Three Times Weekly Dosing in Genotype 1 HCV Patients

2008-11-21 09:54:17

Daily Interferon Plus Ribavirin Is More Effective Than Three Times Weekly Dosing
in Genotype 1 HCV Patients But Not in Those with Genotype 2 and 3
The current standard of care for treatment of chronic hepatitis C is
peginterferon injection once weekly plus ribavirin taken orally twice daily. In
the use of standard interferon, 3 times weekly injections (plus oral ribavirin
twice daily) are FDA-approved.
The aims of the present study were:
1) To determine the sustained virologic response to IFN alfa-2b (3 MU TIW) and
RBV for 48 weeks in veterans with chronic HCV,
2) To evaluate whether 3 MU of daily IFN in combination with RBV for 24 weeks
is superior to standard combination therapy; and
3) To determine the impact of HCV therapy on health-related quality of life
(HRQOL).
158 IFN naive patients from 11 VA Medical Centers were randomized to receive
either 3 MU of IFN alfa-2b QD plus RBV (1000 - 1200 mg/d) for 24 weeks (daily
therapy group) or 3 MU of IFN alfa-2b TIW plus RBV (1000 - 1200 mg/d) for 24
weeks (genotype 2 & 3) or 48 weeks (genotype 1) (standard therapy group). HRQOL
was measured using the Hepatitis QOL Questionnaire.
The proportion of patients with genotype 1 (78.2% vs. 80.0%), number of patients
with cirrhosis (10.3% vs. 10.0%), mean HCV viral load (1.8 vs. 2.0 x 106
copies/ml, and proportion of African American patients (26.9% vs. 35.0%) did not
differ significantly.
The virologic response rates at the end of treatment in the daily IFN group were
higher than in the standard group for all genotypes (46.2% vs. 23.8%, P = 0.003)
and for those with genotype 1 (37.7% vs. 12.5%), but did not differ for those
with genotype 2 and 3 (76.5% vs. 68.8%).
Similarly, the sustained virologic response rates 24 weeks after treatment in
the daily IFN group were higher than in the standard group for all genotypes
(30.8% vs. 16.3%) and for those with genotype 1 (19.7% vs. 6.3%), but did not
differ for those with genotype 2 and 3 (70.6% vs. 56.3%).
The proportion of patients who completed therapy did not differ between groups
(82.1% vs. 80.0%). Both daily and standard therapies were associated with
significant improvements in several domains of HRQOL.
Conclusions: The sustained virologic response to IFN alfa-2b 3 MU TIW and RBV in
veterans with chronic HCV is lower than the response rates reported in
non-veterans.
Daily administration of 3 MU of IFN alfa-2b in combination with RBV for 24 weeks
is superior to standard IFN alfa-2b 3 MU TIW and RBV for 48 weeks in veterans
with genotype 1.
In contrast, daily therapy was no better than standard therapy for patients with
genotype 2 and 3. In our patient population, treatment with combination therapy
was associated with significant improvements in HRQOL.
05/28/03
Reference
EJ Bini and others. Efficacy of Daily Interferon in Combination with Ribavirin
in Patients with Chronic Hepatitis C: Final Results of A VA Multicenter Study.
Abstract T1219 (poster). Abstracts of Digestive Disease Week 2003. May 17-22,
2003. Orlando, FL, USA.
http://www.hivandhepatitis.com/hep_c/news/053003a.html
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/13/2003

African Americans and Asians with Cirrhosis Have Higher Risk for Liver Cancer

2008-11-21 06:28:10

African Americans and Asians with Cirrhosis Have Higher Risk for Liver Cancer
The incidence of hepatitis C cirrhosis (HCC) is rising in the US with HCV
infection accounting for one-third of the cases. Early detection with screening
may offer the best hope for treatment and improved survival.
Identifying high-risk patients is an essential requirement for a cost-effective
screening program. No study to date has examined race as a potential risk factor
for HCC in a diverse U.S. population with HCV cirrhosis.
In this study, researchers performed a hospital-based, clinic-based case-control
study of 507 patients with HCV cirrhosis at 4 study centers using pathology
records, ICD-9 diagnosis, and patient visits to the study centers. Hepatitis B
carriers and patients with chronic hepatitis B, HIV or other malignancies were
not included in this study.
Cases were confirmed by cytology, histology and/or by the presence of focal
hypervascular hepatic mass (on biphasic CT, MRI and/or angiogram) and elevated
AFP. HCC was ruled out in controls by negative AFP and imaging studies.
Multivariate logistic regression was employed to examine associations between
HCC and race. Adjustment was made for age, gender, severity of liver disease
(MELD score, Child class), moderate-to-heavy alcohol use, and study centers. For
all variables, values at diagnosis were obtained for HCC cases and at first
negative AFP and x-ray for controls.
The investigators identified 205 HCC cases and 264 controls without HCC.
Thirty-eight patients could not be classified as cases or controls based on
above criteria and were excluded.
HCC patients were significantly older (median age=59 vs. 52, p < 0.001), more
likely to be male (84% vs. 71%, p=0.001), more likely to be Child class C (57%
vs. 43%, p=0.001), and had slightly higher MELD score (median MELD=11 versus 10,
p=0.05).
There was no significant association between alcohol use or Hispanic race (n=66)
and HCC compared with Caucasian (n=274). After adjustment was made for age,
gender, MELD score, Child class, moderate-to-heavy alcohol use, and study
centers, multivariate OR was 3.0 for African Americans (n=38, p=0.003) and 5.7
for Asians (n=83, p<0.0001) as predictors for HCC.
The authors conclude, "African Americans and Asians with HCV cirrhosis may have
3 and 6 times higher risk for HCC as compared to their Caucasian counterparts -
independent of age, gender, severity of liver disease, and alcohol use.
"Genetic study of liver cancer in a racially diverse population should be
carried out, and high-risk ethnic patients may be among those with HCV cirrhosis
who would benefit the most from HCC screening."
05/28/03
Reference
H Mindie and others. Racial Differences in Risk for Liver Cancer in Patients
with Hepatitis C Cirrhosis: A Multicenter Case-Control Study. Abstract 121
(oral). Abstracts of Digestive Disease Week 2003. May 17-22, 2003. Orlando, FL,
USA.
http://www.hivandhepatitis.com/hep_c/news/053003b.html
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/14/2003

Chat reminder!, 4/23/2006, 6:00 pm

2008-11-20 20:10:01

Reminder Reminder from the Calendar of HepCingles2
Chat reminder!
Sunday April 23, 2006
6:00 pm - 10:00 pm
This event repeats every week.
The next reminder for this event will be sent in 18 hours, 3 minutes.

Needle points

2008-11-20 13:58:02

Needle points
Tuesday, March 28, 2006
If the Trib is going to make claims about hepatitis C and HIV rates in Allegheny
County, it should do its homework ("The needle-exchange program: This is
'success'?" March 24 and TribLIVE.com).
Rising numbers of positive hepatitis C tests almost certainly reflect larger
numbers of people being tested. They are no fair measure of levels of hepatitis
C in the population.
Similarly, simply giving a number of positive HIV tests fails to indicate how
many were linked to injection drug use as opposed to other risk factors. And
again, results of voluntary tests, where only those who seek testing are tested,
do not measure levels of a disease in the population.
The numbers presented in the Trib's editorial say nothing about the
effectiveness or lack of effectiveness of needle exchange in Allegheny County.
To present numbers of positive test results with no indication of how they were
derived and no context for interpreting them is worse than sloppy; it is
irresponsible.
Needle exchange modeled on the latest research is our best protection against
the spread of hepatitis C. That is exactly what Prevention Point Pittsburgh
provides. The best response to finding cases of hepatitis C is not less needle
exchange, but more.
Caroline Jean Acker
Highland Park
The writer is board president of Prevention Point Pittsburgh (pppgh.org), a
private organization that provides needle exchange and overdose prevention
services.
http://pittsburghlive.com/x/tribune-review/s_437322.html

The Influence of Viral Genotypes and Rejection Episodes on the Recurrence of Hepatitis C After Liver Transplantation

2008-11-20 13:52:31

The Influence of Viral Genotypes and Rejection Episodes on the Recurrence of
Hepatitis C After Liver Transplantation
The aim of this study was to report the influence of hepatitis C virus (HCV)
genotype and rejection episodes on the outcome of orthotopic liver
transplantation (OLT), hepatitis recurrence and progression to graft cirrhosis
after OLT.
Fifty-three patients who all had undergone OLT for end-stage liver cirrhosis
were selected for this study. Hepatitis C genotype was determined. Recurrent
hepatitis and rejection were diagnosed based on elevated liver function tests
and a liver biopsy.
The patients were followed up for a mean of 51.9 ± 34.3 months. The cumulative
survival rate was no different in OLT for hepatitis C and OLT for all other
liver diseases.
After OLT, serum HCV RNA was detected in 93%. Histological recurrence occurred
in 85% of all patients. The 1-, 3-, and 5-year recurrence rates were 48%, 77%,
and 85%, respectively.
Of the 41 patients with recurrent hepatitis C, 4 (10%) had cirrhosis, 18 (44%)
had hepatitis with fibrosis, and 91 (46%) had hepatitis without fibrosis at the
end of follow-up. A total of 32% of the patients were infected by HCV genotype
1b and 68% by other HCV genotypes.
The recurrence rates were significantly higher in patients infected with
genotype 1b than in those with other genotypes (p = 0.04).
Twenty of 48 patients (42%) experienced acute rejection. There was a strong
association between the number of rejection episodes and the incidence of
HCV-related cirrhosis (p < 0.01).
The authors conclude, "Our findings showed the genotype 1b to result in a higher
recurrence rate after OLT. On the other hand, rejection episodes were associated
with a more rapid progression to graft cirrhosis."
The Queensland Liver Transplant Service, Princess Alexandra Hospital, Ipswich
Road, Woolloongabba, Qld 4102, Australia, and Second Department of Surgery,
Juntendo University, School of Medicine, Tokyo, Japan.
06/02/03
Reference
H Sugo and others. The Influence of Viral Genotypes and Rejection Episodes on
the Recurrence of Hepatitis C After Liver Transplantation. Surgery Today 33(6):
421-425. May 2003.
http://www.hivandhepatitis.com/hep_c/news/060203c.html
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/13/2003

National Guard to Host Seminar on Hepatitis Today

2008-11-20 09:13:42

National Guard to Host Seminar on Hepatitis Today
Maha Akeel, Arab News
JEDDAH, 23 April 2006 - The preventive medicine department of the National
Guard Health Affairs in the Western Region is hosting today a seminar entitled
"Hepatitis: Concepts and Meanings."
The seminar takes place under the support of Princess Adila bint Abdullah,
chairman of the National Charity Organization for Home Health Care. Its purpose
is to raise public awareness of hepatitis and correct misconceptions.
Hepatitis is a viral inflammation of the liver. Several different viruses,
called A, B, C, D, and E, cause acute, or short-term, viral hepatitis. Hepatitis
B, C, and D can lead to chronic hepatitis, in which the infection is prolonged,
sometimes lifelong, and possibly fatal. Hepatitis A and E are spread through
food and water while B, C and D are transmitted through the blood and by having
unprotected sex.
Hepatitis A is the most common in the world. It affects around 1.4 million
people annually, especially when people travel in countries where the rate of
infection is high.
Hepatitis B is, after tobacco, the second leading cause of cancer and it
is more contagious than the HIV virus. Hepatitis C is the most prevalent liver
disease in the world with 270 to 300 million cases. The World Health
Organization considers Hepatitis C an epidemic. It is often called the "silent"
epidemic because it can infect a patient for decades before being discovered.
Some 20 to 30 percent of people with chronic Hepatitis C will eventually face
life-threatening symptoms.
In Saudi Arabia, according to recent statistics, there are 500,000 people
with Hepatitis C, representing 2.7 percent of world's Hepatitis patients. There
is no vaccine for Hepatitis C; the only way to prevent it is to reduce the risk
of exposure to the virus.
"The seminar targets all sectors of society and to ensure that the
contents and meanings reach all sectors, the National Guard Health Affairs has
arranged with the Education Administration in Jeddah to send a teacher from
every high school to attend the seminar. These teachers are then expected to use
what they learn at the seminar to educate their students about the disease,"
said Dr. Khadija Salim, community medicine consultant and the seminar's
coordinator.
http://www.arabnews.com/?page=1&section=0&article=81136&d=23&m=4&y=2006&pix=king\
dom.jpg&category=Kingdom

Facing up to serious condition

2008-11-19 21:34:09

Facing up to serious condition
AN eye-catching photographic exhibition urged people in Cambridge to face up to
the risks of a little-known but serious infection.
Mother-of-two Karen Peacock unveiled the exhibition showing the faces of people
with hepatitis C.
Karen, 41, who was diagnosed with the infection in 2003, was one of the people
featured in the FaCe It campaign photographs.
She had undergone unsafe tattoos and body piercings - both potential sources of
the infection which affects an estimated 200,000 people in England.
Karen, who is involved with the Hep Cam Support Group, suffered from severe
fatigue, aches and pains for many years before her diagnosis.
She said: "I did not connect it with hepatitis C because I did not know about
it.
"I was absolutely shocked when I was diagnosed and was given a small leaflet
with not very much information in it. I began looking it up on the internet and
was terrified by some of the things I read.
"If people are made more aware of it perhaps they can deal with a diagnosis
without the fear I had."
Hepatitis C, which can also be transmitted through injecting drugs using shared
equipment and from blood transfusions carried out before September 1991, can
cause serious liver damage.
The exhibition, which ran at Christ's Pieces, Cambridge, yesterday (Friday, 21
April) and today (Saturday, 22 April), is part of a national Government
campaign.
Dr Graeme Alexander, a consultant hepatologist at Addenbrooke's Hospital in
Cambridge, said: "We hope the event will support efforts to prevent new cases of
hepatitis C, diagnose those who are already infected and help those who are
concerned they may be at risk of being infected."
The Hep Cam Support Group can be contacted on 07764 699910.
http://www.cambridge-news.co.uk/news/city/2006/04/22/a9e80762-c7d6-4b7a-9ad2-245\
4e0d12334.lpf

Re: Ruined for life

2008-11-19 20:43:26

Alfie,
As my toddler say's Hapeee Hapeee which means I'm Happy...
And hope you enjoy the tea.
Mike

Interleukin 12 (IL-12) Monotherapy for Nonresponders Has Low Efficacy

2008-11-19 17:36:28

Multicenter Study Finds Interleukin 12 (IL-12) Monotherapy for Nonresponders Has
Low Efficacy and Is Poorly Tolerated
Recombinant human interleukin 12 (IL-12) is an immunomodulatory cytokine that is
active against several viruses. Treatment options in patients with chronic
hepatitis C with nonresponse to interferon (IFN)-based therapy are limited.
Prior dose-ranging studies have indicated drug tolerability and transient
suppression of hepatitis C virus (HCV) RNA by IL-12.
The aim of this study was to determine the safety and efficacy of prolonged
IL-12 therapy in patients who have failed treatment with IFN-alfa ± ribavirin.
A total of 225 patients at 21 U.S. sites who had a history of nonresponse to
IFN-alfa or combination IFN-alfa plus ribavirin for treatment of HCV were
randomized to 500 nanogram/kg IL-12 or placebo subcutaneously twice weekly for
12 weeks.
The groups were then unblinded; patients receiving IL-12 continued for another
36 weeks, and the placebo group received 48 weeks of treatment with IL-12 in an
open-label fashion.
HCV RNA, serum alanine aminotransferase (ALT) level, and a repeat liver biopsy
were assessed at 24 weeks following therapy. Approximately 1% (2 of 160) of
nonresponsive patients enrolled for treatment had a sustained virologic response
to IL-12 therapy, but 3% (7 of 225) developed severe adverse events probably
related to treatment, resulting in early termination of the trial.
Common adverse effects reported by most patients included chills, fever,
fatigue, headache, and arthralgia. At termination of the study, 160 patients had
received at least 8 weeks of treatment with IL-12. Paired liver biopsy specimens
were available for evaluation in 54 patients, but there were no significant
changes in Knodell fibrosis or histologic activity index (HAI) scores.
In conclusion, IL-12 as monotherapy at the doses used in this trial for chronic
hepatitis C has low efficacy, was poorly tolerated, and is unlikely to provide
an alternative to conventional IFN-based therapy.
06-02-03
Reference
PJ Pockros and others. A multicenter study of recombinant human interleukin 12
for the treatment of chronic hepatitis C virus infection in patients
nonresponsive to previous therapy. Hepatology 37 (6):1368-1374. June 2003.
http://www.hivandhepatitis.com/hep_c/news/060203a.html
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.481 / Virus Database: 277 - Release Date: 05/13/2003

tired of lurking : o )

2008-11-19 05:52:34

Hi Everybody,
First I would like to thank everyone for all the effort that goes
into the group. I am sure there are always plenty of people like me
that for one reason or another want to stay in the background. All of
the posts are helpful in one way or another. So "For Real" thank you
one and all.
I was diagnosed about 2 years ago. I have only recently ( when i
joined this group ) made arrangements to see a doctor. I don't even
know if I called the right kind of doctor. I made the appointment at
a Hemotologist/Oncologist, was this correct? I ask because when I
went to my "family" doc, internal medicine actually, for a referall
he said he was going to do some blood tests and if they were all
right I did not need to see anyone else besides him. I have been
having a lot of things going on medically in the way of symptoms that
i thought i should go to a specialist. I have intense abdominal pain
and bloating and cramping. My legs are swollen with fluid and if I
press with my fingertip on my leg an indentation remains. I have an
abcess infected in my shoulder exactly where I had shoulder surgery
and the infection will not clear with oral antibiotics, the infection
was cultured at the hospital and it should have responded to
antibiotics. I have a rash in my groin area that even my doctor
thought was jock itch but was not and that will not go away either. I
have dry itchy spots on my legs that i cannot get to completely heal
up even with prescription creme.
I guess thats enough for now, i just wanted to know if these symptoms
sound familiar, I know i have seen some of them listed as possible
symtoms, i just wanted to ask because i respect this groups opinions.
I also need very badly to know if my family doctor was telling me
right about not seeing a specialist unless my blood was off. Because
all this stuff has to be caused by something.
I am so depressed about this sometimes I could just scream!!! I had
an accident at work in '94 and was just beginning to have a normal
life again when I got a phone call from a prison nurse informing me
a "friend" of mine had just been diagnosed and she thought i should
know because we had slept together a few times before she got locked
up, so i caught it from having sex I don't care how slim the odds
are.
I thought i needed to know the genotype and viral load and all that
stuff which was why i thought i needed a specialist. Any guidance
would be much appreciated. thanks for letting me vent. Its lonely
because there is noone around this city called Neaderthalville i live
in, to talk to, so thanks.
Peace Out!!

Exercise and blonding!

2008-11-18 23:38:22

I need to get off my butt and exercise more too :-) I have uncovered the
treadmill downstairs but it is one that you legs have to do all the work
(not electric) and with my leg pains it makes it harder! I also plan to
get back into the yoga scene this summer. Have lots of great plans........
now I just have to follow through :-) Take care of yourselves!
So Mykal......... you have gone blonde?? LOL Me too! Love that Summer
Blonde by Clairol :-)
Peace and Love,
Pam
Dogs come when they're called. Cats take a message and get back to you. --
Missy Dizick

Re: [HepCingles2] Re:Teri/All(Dana?Update/Mykal?Update)

2008-11-18 20:24:42

Sorry to hear you aint doin well Dana UTI? is that what azo is for LOL
Take good care of your self and I'll catch you later...Mykal;

Re:Teri/All(Dana?Update/Mykal?Update)

2008-11-18 16:10:04

Teri and All,
Thank you for checking in on me. Sorry have been so lapse on checking in. I
had to go to the Doc for another severe UTI. If you don't know what that is, ya
don't want too! LOL But any longer I would of been in the hospital. Am on
antibiotics and doing okay, just wear me out along with everything else I have
going! Geez, don't know if I will ever get done. Hope everyone is doing well,
welcome all new members and miss you guys, trying really hard to get back to
post, but not doing very well! Please forgive me! I know, I also owe private
mails! Don't yell! Don't Yell!.......LMAO
Okay, about Mykal! His sister called this morning and he got to go to her house
last night from where he was. She said he is doing fine and I shall try to talk
to him later. Talked to him the other day and is doing well and sends his love
and misses everyone!
Hugs, prayers and smiles to all..........Dana in PA
Teri Covert <covert@...
Dear Dana,
Getting a little concerned about you, last comment was about something wrong
with you and going to the Dr.? So what's going on??? Please let us know, also
any info on Mykal would be appreciated, know your busier than you should be.
Hope everything is ok!
Love,Teri
,
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 4/24/03

hep c vets

2008-11-18 09:18:33

All,
A new group for hepatitis c infected veterans was startedabout 3